Document Detail

S100b as a prognostic biomarker in outcome prediction for patients with severe traumatic brain injury.
MedLine Citation:
PMID:  23190274     Owner:  NLM     Status:  MEDLINE    
As an astrocytic protein specific to the central nervous system, S100b is a potentially useful marker in outcome prediction after traumatic brain injury (TBI). Some studies have questioned the validity of S100b, citing the extracerebral origins of the protein as reducing the specificity of the marker. This study evaluated S100b as a prognostic biomarker in adult subjects with severe TBI (sTBI) by comparing outcomes with S100b temporal profiles generated from both cerebrospinal fluid (CSF) (n = 138 subjects) and serum (n = 80 subjects) samples across a 6-day time course. Long-bone fracture, Injury Severity Score (ISS), and isolated head injury status were variables used to assess extracerebral sources of S100b in serum. After TBI, CSF and serum S100b levels were increased over healthy controls across the first 6 days post-TBI (p ≤ 0.005 and p ≤ 0.031). Though CSF and serum levels were highly correlated during early time points post-TBI, this association diminished over time. Bivariate analysis showed that subjects who had temporal CSF profiles with higher S100b concentrations had higher acute mortality (p < 0.001) and worse Glasgow Outcome Scale (GOS; p = 0.002) and Disability Rating Scale (DRS) scores (p = 0.039) 6 months post-injury. Possibly as a result of extracerebral sources of S100b in serum, as represented by high ISS scores (p = 0.032), temporal serum profiles were associated with acute mortality (p = 0.015). High CSF S100b levels were observed in women (p = 0.022) and older subjects (p = 0.004). Multivariate logistic regression confirmed CSF S100b profiles in predicting GOS and DRS and showed mean and peak serum S100b as acute mortality predictors after sTBI.
Akash Goyal; Michelle D Failla; Christian Niyonkuru; Krutika Amin; Anthony Fabio; Rachel P Berger; Amy K Wagner
Related Documents :
23159144 - Urine biochemistry in septic and non-septic acute kidney injury: a prospective observat...
2690904 - Pharmacokinetics of angiotensin converting enzyme inhibitors.
3024874 - Adrenergic activity and aldosterone regulation: no evidence for an alpha-1 adrenoceptor...
6366404 - The hypotensive effect of captopril in hypertensive patients is age-related.
2870974 - Somatostatin inhibits the dermorphin-stimulated thyrotropin release in man.
24732714 - Fetuin a as a new marker of inflammation in hashimoto thyroiditis.
Publication Detail:
Type:  Journal Article; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, U.S. Gov't, P.H.S.    
Journal Detail:
Title:  Journal of neurotrauma     Volume:  30     ISSN:  1557-9042     ISO Abbreviation:  J. Neurotrauma     Publication Date:  2013 Jun 
Date Detail:
Created Date:  2013-06-19     Completed Date:  2014-01-23     Revised Date:  2014-06-03    
Medline Journal Info:
Nlm Unique ID:  8811626     Medline TA:  J Neurotrauma     Country:  United States    
Other Details:
Languages:  eng     Pagination:  946-57     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Biological Markers / blood*,  cerebrospinal fluid*
Brain Injuries / blood*,  cerebrospinal fluid*,  mortality
Cohort Studies
Enzyme-Linked Immunosorbent Assay
Glasgow Outcome Scale
S100 Calcium Binding Protein beta Subunit / blood*,  cerebrospinal fluid*
Grant Support
R49/CCR323155//PHS HHS
Reg. No./Substance:
0/Biological Markers; 0/S100 Calcium Binding Protein beta Subunit; 0/S100B protein, human

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Impact of cross-sectional root canal shape on filled canal volume and remaining root filling materia...
Next Document:  Latest treatment for lower urinary tract dysfunction: Therapeutic agents and mechanism of action.